We previously demonstrated in proof-of-concept animal experiments that inhibition of the calcium-activated potassium channel KCa3.1 may be a potential therapeutic approach for reducing stroke-associated neuroinflammation and reperfusion damage [9, 10] and are therefore proposing KCa3.1 as a target for immunocytoprotection. Here, KCNN4 is linked to stroke disorder.